This phase I dose escalation and expansion study is evaluating a targeted therapy (lemzoparlimab), with or without the steroid dexamethasone, in combination with other targeted therapies (pomalidomide, carfilzomib or daratumumab) in adults with multiple myeloma.
This trial is treating patients with relapsed or refractory multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Each treatment arm in this trial receives a different treatment combination depending on stage of the study and eligibility. The study includes a dose escalation phase to determine the best dose of lemzoparlimab, followed by a dose expansion phase to confirm the dose. In the dose escalation arms, participants will receive intravenous (IV) lemzoparlimab with or without dexamethasone (orally or via IV) in combination with pomalidomide (orally) or carfilzomib (via IV) or daratumumab (via subcutaneous injection) in 28-day cycles. In the Dose Expansion arms, participants will receive the same treatments as in the Dose Escalation phase, to confirm the dose.
Recruiting Hospitals Read More